The biggest obstacle holding back the entire RNA field, including mRNA and oligonucleotides, is the challenge of delivering these therapies beyond the liver. A breakthrough in novel delivery mechanisms is considered more critical for unlocking the modality's therapeutic potential than discovering new RNA molecules.

The next breakthrough in RNA therapeutics won't come from a single innovation. It requires combining two key elements: a 'programmable' mRNA payload designed to be active only in specific cells, and a targeted delivery system to get it there. This two-part solution represents the next generation of in-vivo therapies.

Phillip Sharp notes that Alnylam, founded in 2002, took 16 years to get its first drug approval and will take 23 years to become profitable. This long timeline underscores the massive capital and persistence required to translate a foundational scientific discovery into a commercial success.

Phillip Sharp explains that the decision to co-found Alnylam was driven by the enormous potential of RNAi to treat countless diseases. This massive upside of changing medicine dwarfed the downside risk of the company failing, making it a compelling venture despite the odds.

The typical path for a new, high-risk biology is to test it in patients with no other options, like in oncology. The COVID-19 pandemic forced a massive deviation from this norm. For the first time, a completely new class of medicine (mRNA) was deployed at scale in healthy individuals, not the sickest.

Facing industry-wide skepticism in 2010, Alnylam implemented a highly disciplined R&D strategy. They focused exclusively on targets that met strict criteria: liver expression (where delivery worked), human genetic validation (to de-risk biology), and an early biomarker. This strategic focus was key to their survival and success.

The company's mRNA and lipid nanoparticle (LNP) platform can leverage the massive manufacturing and distribution infrastructure built globally for COVID-19 vaccines. This solves a major scalability bottleneck that plagues traditional cell therapies, making their advanced treatment potentially as accessible and distributable as a vaccine.

While large pharma companies invested heavily in RNAi and failed to produce candidates, Alnylam maintained a singular focus. They pushed their technology into human trials to learn and validate it, ultimately succeeding where better-funded competitors with a less focused, product-driven approach failed.

The high probability of success for Alnylam's drugs seems simple now but was the result of years of work. They had to perfect a delivery modality, prove its safety, and identify validated targets in an accessible tissue (the liver). Only after solving these three monumental challenges did drug development become repeatable.